myviralspiral3.com

New York, NY (PRWeb) 20 December 2011

New York Center for Human Reproduction (CHR) is pleased to announce that the U.S. Patent and Trademark Office has accepted a patent application for the treatment of infertility, serial number 8067400, titled androgen receptor therapy in women.

requirements of this permit application – the latter is based on research Chrs dehydroepiandrosterone (DHEA) in women with infertility – focused on methods to reduce the rate of aneuploidy (chromosomal abnormalities) in human embryos, decreases during pregnancy and improve pregnancy rates by androgens given for at least two months.

, it means that DHEA has been approved (in the second patent issued CHR) infertility treatment to increase pregnancy, reduce the time of conception and reduction of chromosomal abnormalities in embryos. DHEA is the first agent ever approved to reduce chromosomal abnormalities in human embryos. Since about 85% of all human thought that abortion due to chromosomal abnormalities, DHEA can be expected to reduce abortion rates.

CHR investigators noticed a reduction in the risk of miscarriage after DHEA supplement [Gleicher et al, abortion rates of dehydroepiandrosterone (DHEA) replacement therapy in women with reduced ovarian reserve. case control study. Reprod Biol Endocrinol 2009;. 7:108]

second patent CHR only confirms the growing importance of DHEA in female infertility, in addition, we had the opportunity to follow our research for more than seven years, notes Norbert Gleicher, MD, Medical Director and Founder of Chrs, and one of the inventors listed in the DHEA the patent. He suggests that the further approval of the claim that DHEA reduces chromosomal abnormalities in the embryo provides an excellent opportunity, because this research suggests that DHEA supplement May benefit not only women with infertility.

picking up on that thought, David H. Barad, MD – Clinical Director Chrs IVF and other inventors listed on patents – evidence of chromosomal abnormalities in embryos increases as women age. Therefore, abortion is increased in parallel. DHEA supplements may also be useful in older women with normal fertility trying to conceive on their own. “It adds to the birth of a multivitamin in the future may also contain DHEA.

Center for Human Reproduction (http://www.centerforhumanreprod.com) is a leading infertility center in New York with global customers, known for large clinical trials program. The program is a series of important breakthroughs in the IVF procedure. Dr. Gleicher is available for further comment.

###

Austin, Texas (PRWeb) 27 December 2011

Texas Fertility Center Reproductive Endocrinologists Dr. Kayler Silverberg and Thomas Vaughn were asked to work with the Texas Institute of Robotic Surgery at St. David North Austin Medical Center to use the da Vinci robotic surgical Fertility of patients in Central Texas. da Vinci Robotic Surgery offers a sophisticated alternative to traditional open surgery or laparoscopic surgery for many conditions that can affect fertility, including the uterus, endometriosis and pelvic adhesions.

Dr. Silverberg and Vaughn will be at home cutting edge of surgical patient care in the use of fertility da Vinci system made and sold Intuitive Surgical (ISRG).

Da Vinci robot is a potential quantum leap forward for endoscopic surgery, said Dr. Silverberg. This little invasive technology is an amazing 3D optics and increasing surgical dexterity that enables surgeons to achieve a variety of complex surgical procedures with greater ease and security. We believe that there are many applications for the Da Vinci robot in the treatment of infertility, and we hope that significantly improve patient care.

Robotic surgery involves the use of robot arms 03:57 expect a surgeon from a remote computer. A robotic arm includes a camera, which increases the surgical field to ensure the fertility doctor has increased three-dimensional, high-definition digital images. Other hand using specially designed surgical instruments that allow doctors to measure the movement and perform procedures with greater precision and agility.

While robots have been employed for routine gynecological procedures such as hysterectomy a few years, recent advances in technology allow for more complex procedures to be performed by robots. Newer technologies, such as the employment of lasers to improve the definition and dissection, hold tremendous promise not only for the treatment of infertility, but also for the treatment of various other benign and cancerous conditions.

Texas Fertility Center

Texas Fertility Center (TFC), one of the nation’s leading full-service infertility practices, providing advanced reproductive endocrinology and infertility services to patients in Texas, the southwestern United States and the Americas. Since 1980, TFC has been recognized nationally for outstanding pregnancy, cutting-edge laboratory techniques and new research programs. For more information, see http://www.txfertility.com.

###